Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist
Authors
Solomon, Daniel H.Rassen, Jeremy A.
Kuriya, Bindee
Chen, Lang
Harrold, Leslie R.
Graham, David J.
Lewis, James D.
Lii, Joyce
Liu, Liyan
Griffin, Marie R.
Curtis, Jeffrey R.
UMass Chan Affiliations
Department of Medicine, Division of RheumatologyMeyers Primary Care Institute
Document Type
Journal ArticlePublication Date
2013-11-01Keywords
Heart FailureArthritis, Rheumatoid
Recombinant Fusion Proteins
Tumor Necrosis Factor-alpha
Cardiovascular Diseases
Immune System Diseases
Musculoskeletal Diseases
Rheumatology
Metadata
Show full item recordAbstract
BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)alpha, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF. We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA). METHODS: We used data from four different US healthcare programmes. Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD). These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics. RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates. The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14). The HR was also not elevated in subjects with a history of HF. But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036). Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1/=5 mg HR 1.54 (95% CI 1.09 to 2.19). CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.Source
Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2013 Nov 1;72(11):1813-8. doi: 10.1136/annrheumdis-2012-202136. Link to article on publisher's site
DOI
10.1136/annrheumdis-2012-202136Permanent Link to this Item
http://hdl.handle.net/20.500.14038/37199PubMed ID
23155221Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1136/annrheumdis-2012-202136